Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.alit.2024.08.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy.
J Allergy Clin Immunol
November 2024
Division of Allergy and Clinical Immunology, Brigham & Women's Hospital and Department of Medicine, Boston, Mass; Harvard Medical School, Boston, Mass; Channing Division of Network Medicine, Brigham & Women's Hospital and Department of Medicine, Boston, Mass. Electronic address:
Background: There have been multiple reports of the anti-IL-4Rα agent, dupilumab, being associated with the onset and/or progression of cutaneous T-cell lymphoma (CTCL).
Objective: We sought to evaluate safety signals associated with dupilumab, with a focus on CTCL, and to evaluate the possible underlying mechanism or mechanisms for the potential association.
Methods: First, we used the Food and Drug Administration's pharmacovigilance database, FAERS (FDA Adverse Event Reporting System), to evaluate whether dupilumab was associated with CTCL, including both positive outcome controls (conjunctivitis, eosinophilia, and arthralgia) and exposure controls (other medications with similar indications, including JAK inhibitors and the anti-IL-13 agent, tralokinumab) to evaluate confounding bias.
Dupilumab-related eosinophilia in patients with severe asthma: Post-marketing surveillance in Japan.
Allergol Int
January 2025
Sanofi K.K., Tokyo, Japan.
Dupilumab-associated hypereosinophilia in severe asthma.
ERJ Open Res
July 2024
Allergy, Asthma and Clinical Immunology Service, Alfred Health, Melbourne, Australia.
https://bit.ly/3JgZ5Ya.
View Article and Find Full Text PDFCombination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis.
Autoimmun Rev
March 2024
Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy.
Monoclonal antibodies targeting type 2 inflammation are promising treatments for eosinophilic-associated diseases. There is growing interest in the potential benefits of combining two biologics to treat patients with poorly controlled conditions. We present a case of a 54-year-old female patient affected with a relapsing-refractory ANCA myeloperoxidase positive eosinophilic granulomatosis with polyangiitis (EGPA), presenting with difficult-to-treat asthma and rhino-sinusitis manifestations.
View Article and Find Full Text PDFElevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease.
J Dermatolog Treat
August 2022
Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Introduction: Transient eosinophilia is not uncommon in patients with moderate-to-severe atopic dermatitis (AD) treated with dupilumab.
Methods: A retrospective, single center, observational study was conducted to assess the difference in terms of absolute eosinophil count (AEC) change at 4 months and at 12 months, relative to the baseline, in predefined subgroups of patients affected by moderate-to-severe AD treated with dupilumab.
Results: Complete data for 373, 289 and 210 patients were available at the baseline, 4 months and 12 months, respectively.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!